ASCO 2024 | Future potential and challenges of AdAPT-001: evaluating efficacy and exploring new cancer types
Anthony Paul Conley, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discussed the future potential and challenges of AdAPT-001 in cancer therapy. He emphasized the need to evaluate the efficacy signals across various tumors and consider exploring other cancer types. Dr Conley envisions AdAPT-001 as an ideal treatment for patients previously exposed to immunotherapy, aiming to rekindle their prior responses. Given its favorable safety profile, AdAPT-001 could be a beneficial addition for patients who have endured significant side effects from existing therapies.This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
